The long term goal is to extend the useful shelf life of human red blood
cells. The specific aims are: l) to study the effect of ammonium (NH4+)
and phosphate (Pi) on nucleotide and carbohydrate metabolism of RBCs; 2)
to study membrane vesiculation and aminophospholipid flip flop during
blood bank storage; 3) to identify correlated changes in the
phosphinositides; 4) to ascertain the development of protein oxidation
during storage; 5) to perform autologous in vivo viability studies. Units
of packed red blood cells (PRBCs) will be stored with experimental
additive solutions (EASs) in which the concentrations of NH4+ and Pi will
be varied. The in vitro studies will include measurements at intervals
up to 12 weeks of adenosine triphosphate 2,3-diphosphoglycerate, mean
corpuscular volume, hemolysis, vesiculation and pH. 51Cr-labeled RBCs
will be used in paired viability studies comparing selected EASs with a
commercial additive solution, Adsol. For the metabolic studies, adenine-
8-14c will be used to measure the turnover of purine nucleotides and
nucleosides. The levels of glucose-6-PO4 and fructose-6-PO4 will be used
as indicators of phosphofructokinase activity. The ratios of lactate to
pyruvate and the oxidized to the reduced form of nicotinamide adenine
dinucleotide (NAD:NADH) will be used to gauge the activity of 3-
phosphoglyceraldehyde dehydrogenase. Trinitrobenzenesulfonic acid will
be used to quantitate the change in accessibility of phosphatidyl serine
and ethanolamine during storage. Thin layer chromatography will be
performed to separate and quantify the phosphinositides. Spectrin
oxidation will be assessed using thiol disulfide exchange chromatography
followed by gel electrophoresis. These studies will serve to enhance
understanding of the metabolic changes affecting RBCs during blood bank
storage. The resulting health benefits will be: 1) more effective
operation of autologous donor programs. Longer effective shelf life of
RBCs will make it possible to store more units preoperatively if needed
and permit longer intervals between donations when the patient's clinical
status makes this desirable; 2) the longer shelf life will make it
possible to maintain the blood inventories of outlying hospitals more
effectively with less outdating. Loss of blood by outdating still
averages 10 percent in such situations.
No Sub Projects information available for 5R01HL044897-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL044897-05
Patents
No Patents information available for 5R01HL044897-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL044897-05
Clinical Studies
No Clinical Studies information available for 5R01HL044897-05
News and More
Related News Releases
No news release information available for 5R01HL044897-05
History
No Historical information available for 5R01HL044897-05
Similar Projects
No Similar Projects information available for 5R01HL044897-05